Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-adamantyl)-4- hydroxyphenyl]-3-chlorocinnamic acid

Journal of Medicinal Chemistry

Volumn 54, Issue 11, 2011, Pages 3793-3816

  Xia, Zebin ^a   Farhana, Lulu ^b   Correa, Ricardo G ^a   Das, Jayanta K ^b   Castro, David J ^a   Yu, Jinghua ^a   Oshima, Robert G ^a   Reed, John C ^a   Fontana, Joseph A ^b   Dawson, Marcia I ^a  

^a BURNHAM INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3' (1 ADAMANTYL) 4' HYDROXYPHENYL] 3 CHLOROCINNAMIC ACID; LIGAND; NITROGEN; ORPHAN NUCLEAR RECEPTOR; PHOSPHATE BUFFERED SALINE; PYRIDINE; PYRIMIDINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG SOLUBILITY; DRUG SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; MYELOID LEUKEMIA;

ACRYLATES; ADAMANTANE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CINNAMATES; DRUG DESIGN; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIGANDS; MICE; ORPHAN NUCLEAR RECEPTORS;

EID: 79958096105     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200051z     Document Type: Article

References (78)

1. 1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 1995, 11, 493-504.
2. Zhang,Y.;Huang,Y.;Rishi,A.K.; Sheikh,M.S.; Shroot,B.; Reichert, U.; Dawson,M. I.; Poirer,G.; Fontana, J. A. Activation of the p38 and JNK/ SAPK mitogen-activated protein kinase pathways during apoptosis is mediated by a novel retinoid. Exper. Cell Res. 1999, 247, 233-240. (Pubitemid 29393979)
3. Dawson, M. I.; Hobbs, P. D.; Peterson, V. J.; Leid, M.; Lange, C. W.; Feng, K.-C.; Chen, G.; Gu, J.; Li, H.; Kolluri, S. K.; Zhang, X.; Zhang, Y.; Fontana, J. A. Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity. Cancer Res. 2001, 61, 4723-4730. (Pubitemid 32691882)
4. Zhang, Y.; Dawson, M. I.; Mohammad, R.; Rishi, A. K.; Farhana, L.; Feng, K.-C.; Leid, M.; Peterson, V.; Zhang, X.-K.; Edelstein, M.; Eilander, D.; Biggar, S.; Wall, N.; Reichert, U.; Fontana, J. A. Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog. Blood 2002, 100, 2917-2925.
5. Dawson, M. I.; Harris, D. L.; Liu, G.; Hobbs, P. D.; Lange, C. W.; Jong, L.; Bruey-Sedano, N.; James, S. Y.; Zhang, X.-K.; Peterson, V. J.; Leid, M.; Farhana, L.; Rishi, A. K.; Fontana, J. A. Antagonist analogue of 6-[30-(1-adamantyl)-40-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN) family of apoptosis inducers that effectively blocks AHPNinduced apoptosis but not cell-cycle arrest. J. Med. Chem. 2004, 47, 3518-3536. (Pubitemid 38822014)
6. Dawson, M. I.; Xia, Z.; Liu, G.; Fontana, J. A.; Farhana, L.; Patel, B. B.; Arumugarajah, S.; Bhuiyan, M.; Zhang, X.-K.; Han, Y.-H.; Stallcup, W. B.; Fukushi, J.; Mustelin, T.; Tautz, L.; Su, Y.; Harris, D. L.; Waleh, N.; Hobbs, P. D.; Jong, L.; Chao, W.; Schiff, L. J.; Sani, B. P. An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: Effects of modifying its carboxylate group on apoptosis proliferation and protein-tyrosine phosphatase activity. J. Med. Chem. 2007, 50, 2622-2639. (Pubitemid 46896070)
7. Dawson, M. I.; Xia, Z.; Jiang, T.; Ye, M.; Fontana, J. A.; Farhana, L.; Patel, B.; Xue, L.-P.; Bhuiyan, M.; Pellicciari, R.; Macchiarulo, A.; Nuti, R.; Zhang, X.-K.; Han, Y.-H.; Tautz, L.; Hobbs, P. D.; Jong, L.; Waleh, N.; Chao, W.-R.; Feng, G.-S.; Pang, Y.; Su, Y. Adamantylsubstituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: Effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of src homology 2 domain-containing protein tyrosine phosphatase-2 activity. J. Med. Chem. 2008, 51, 5650-5662.
8. Garattini, E.; Gianni, M.; Terao, M. Retinoid related molecules. An emerging class of apoptotic agents with promising potential in oncology: Pharmacological activity and mechanism of action. Curr. Pharm. Des. 2004, 10, 433-448. (Pubitemid 38159873)
9. Benbrook, D. M.; Turman, M.; Guruswamy, S. Flexible heteroarotinoids (Flex-Hets) as anti-cancer and other therapeutic agents. World Patent WO 113627, 2006.
10. Charpentier, B.; Bernardon, J.M.; Eustache, J.;Millois, C.;Martin, B.; Michel, S.; Shroot, B. Synthesis, structure-affinity relationships and biological activities of ligands binding to retinoic acid receptor subtypes. J. Med. Chem. 1995, 38, 4993-5006. (Pubitemid 26018406)
11. WAF1/CIP1 expression in human breast carcinoma cells. Cancer Res. 1996, 56, 5055-5062. (Pubitemid 26374449)
12. Silverman, A. K.; Ellis, C. N.; Voorhees, J. J. Hypervitaminosis A syndrome: A paradigm of retinoid side effects. J. Am. Acad. Dermatol. 1987, 16, 1027-1039. (Pubitemid 17073138)
13. Newton, D. L.; Henderson, W. R.; Sporn, M. B. Structureactivity relationships of retinoids in hamster tracheal organ culture. Cancer Res. 1980, 40, 3413-3425. (Pubitemid 10003725)
14. Verma, A. K.; Shapas, B. G.; Rice, H. M.; Boutwell, R. K. Correlation of the inhibition by retinoids of tumor promoter-induced mouse epidermal ornithine decarboxylase activity and of skin tumor promotion. Cancer Res. 1979, 39, 419-425. (Pubitemid 9095903)
15. Cincinelli, R.; Dallavalle, S.; Merlini, L.; Penco, S.; Pisano, C.; Carminati, P.; Giannini, G.; Vesci, L.; Gaetano, C.; Illy, B.; Zuco, V.; Supino, R.; Zunino, F. A novel atypical retinoid endowed with proapoptotic and antitumor activity. J. Med. Chem. 2003, 46, 909-912. (Pubitemid 36423136)
16. Strickland, S.; Breitman, T. R.; Frickel, F.; Nürrenbach, A.; Hädicke, E.; Sporn, M. B. Structure-activity relationships of a new series of retinoidal benzoic acid derivatives as measured by induction of differentiation of murine F9 teratocarcinoma cells and human HL-60 promyelocytic leukemia cells. Cancer Res. 1983, 43, 5268-5272. (Pubitemid 14230137)
17. Boehm, M. F.; Zhang, L.; Badea, B. A.; White, S. K.; Mais, D. E.; Berger, E.; Suto, C. M.; Goldman, M. E.; Heyman, R. A. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J. Med. Chem. 1994, 37, 2930-2941. (Pubitemid 24297810)
18. Boehm, M. F.; Zhang, L.; Zhi, L.; McClurg, M. R.; Berger, E.; Wagoner, M.; Mais, D. E.; Suto, C. M.; Davies, P. J. A.; Heyman, R. A.; Nadzan, A. M. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J. Med. Chem. 1995, 38, 3146-3155.
19. Renaud, J.-P.; Rochel, N.; Ruff, M.; Vivat, V.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 1995, 378, 681-689.
20. Keidel, S.; Lemotte, P.; Apfel, C. Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping. Mol. Cell. Biol. 1994, 14, 287-298.
21. Green, D. R.; Reed, J. C. Mitochondria and apoptosis. Science 1998, 281, 1309-1312. (Pubitemid 28406816)
22. Li, H.; Kolluri, S. K.; Gu, J.; Dawson, M. I.; Cao, X.; Hobbs, P. D.; Lin, B.; Chen, G.; Lu, J.; Lin, F.; Xie, Z.; Fontana, J. A.; Reed, J. C.; Zhang, X. Cytochrome c release and apoptosis induced by mitrochondrial targeting of nuclear orphan receptor TR3. Science 2000, 289, 1159-1164. (Pubitemid 30650723)
23. Lin, B.; Kolluri, S. K.; Lin, F.; Liu, W.; Han, Y. H.; Cao, X.; Dawson, M. I.; Reed, J. C.; Zhang, X.-K. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/ TR3. Cell 2004, 116, 527-540. (Pubitemid 38264430)
24. Han, Y. H.; Cao, X.; Lin, B.; Lin, F.; Kolluri, S. K.; Stebbins, J.; Reed, J. C.;Dawson,M. I.;Zhang,X.-K. RegulationofNur77nuclear export by c-Jun N-terminal kinase and Akt. Oncogene 2006, 25, 2974-2986. (Pubitemid 43780462)
25. Farhana, L.; Dawson, M. I.; Leid, M.; Wang, L.; Moore, D. D.; Liu, G.; Xia, Z.; Fontana, J. A. Adamantyl-substituted retinoid-related molecules bind small heterodimer partner and modulate the Sin3A repressor. Cancer Res. 2007, 67, 318-325. (Pubitemid 46142790)
26. Lynch, C. J.; Milner, J. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: A basis for p53 haplo-insufficiency. Oncogene 2006, 25, 3463-3470. (Pubitemid 43877049)
27. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. p53 mutations in human cancers. Science 1991, 253, 49-53. (Pubitemid 21917115)
28. Amstrong, R. B.; Ashenfelter, K. O.; Eckhoff, C.; Levin, A. A.; Shapiro, S. S. General and reproductive toxicology of retinoids. In The Retinoids, Biology, Chemistry and Medicine; Sporn, M. B., Roberts, A. B., Goodman, D. S., Eds.; Raven Press: New York, 1994; pp 545-572.
29. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
30. Malik, I.; Hussain, M.; Ali, A.; Toguem, S.-M. T.; Basha, F. Z.; Fischer, C.; Langer, P. Synthesis of 2,3-disubstituted pyrazines and quinoxalines by Heck cross-coupling reactions of 2,3-dichloropyrazine and 2,3- dichloroquinoxaline. Influence of the temperature on the product distribution. Tetrahedron 2010, 66, 1637-1642.
31. Dawson, M. I.; Fontana, J. A.; Zhang, X.-K.; Leid, M.; Jong, L.; Hobbs, P. D. Preparation of cinnamic acids for induction of apoptosis in cancer cells. World Patent WO 048101, 2003.
32. Dawson, M. I.; Hobbs, P.; Derdzinski, K.; Chan, R. L.-S.; Gruber, J.; Chao, W.; Smith, S.; Thies, R. W.; Schiff, L. J. Conformationally restricted retinoids. J. Med. Chem. 1984, 27, 1516-1531. (Pubitemid 15200576)
33. Mukherjee, C.; Biehl, E. An efficient synthesis of benzene fused six-, seven-, and eight-membered rings containing nitrogen and sulfur by benzyne ring closure reaction. Heterocycles 2004, 63, 2309-2318.
34. Macchiarulo, A.; Rizzo, G.; Costantino, G.; Fiorucci, S.; Pellicciari, R. Unveiling hidden features of orphan nuclear receptors: The case of the small heterodimer partner (SHP). J. Mol. Graphics Modell. 2006, 24, 362-372. (Pubitemid 43320551)
35. Torrado, A.; Lamas, C.; Agejas, J.; Jiménez, A.; Díaz, N.; Gilmore, J.; Boot, J.; Findlay, J.; Hayhurst, L.; Wallace, L.; Broadmore, R.; Tomlinson, R. Novel selective and potent 5-HT reuptake inhibitors with 5-HT1D antagonist activity: Chemistry and pharmacological evaluation of a series of thienopyran derivatives. Bioorg. Med. Chem. 2004, 12, 5277-5295. (Pubitemid 39263674)
36. Toto, P.; Gesquiére, J.-C.; Cousaert, N.; Deprez, B.; Willand, N. UFU ('Ullmann-Finkelstein-Ullmann'): A new multicomponent reaction. Tetrahedron Lett. 2006, 47, 4973-4978. (Pubitemid 43841887)
37. Gieseler, F.; Bauer, E.; Nuessler, V.; Clark, V.; Valsamas, S. Molecular effect of topoisomerase II inhibitors in AML cell lines: Correlation of apoptosis with topoisomerase II activity but not with DNA damage. Leukemia 1999, 13, 1859-1863. (Pubitemid 29535272)
38. Amico, D.; Barbui, A. M.; Erba, E.; Rambaldi, A.; Introna, M.; Golay, J. Differential response of human acute myeloid leukemia cell to gemtuzumab ozogamicin in vitro: Role of Chk1 and Chk2 phosphorylation and caspase 3. Blood 2003, 101, 4589-4597. (Pubitemid 36857832)
39. Kastan, M. B.; Radin, A. I.; Kuerbitz, S. J.; Onyekwere, O.; Wolkow, C. A.; Civin, C. I.; Stone, K. D.; Woo, T.; Ravindranath, Y.; Craig, R. W. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res. 1991, 51, 4279-4286.
40. Duong, V.; Licznar, A.; Margueron, R.; Boulle, N.; Busson, M.; Lacroix, M.; Katzenellenbogen, B. S.; Cavaillés, V.; Lazennec, G. ERR and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene 2006, 25, 1799-1806.
41. Weisz, A.; Basile, W.; Scafoglio, C.; Altucci, L.; Bresciani, F.; Facchiano, A.; Sismondi, P.; Cicatiello, L.; Bortoli, M. D. Molecular identification of ERR-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. J. Cell. Physiol. 2004, 200, 440-450. (Pubitemid 39006936)
42. Emi, M.; Kim, R.; Tanabe, K.; Uchida, Y.; Toge, T. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res. 2005, 7, R940-R952.
43. Sala, F.; Zucchetti, M.; Bagnati, R.; D'Incalci, M.; Pace, S.; Capocasa, F.; Marangon, E. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantyl retinoid dervative, in plasma of patients in a phase I study. J. Chromatogr. B 2009, 877, 3118-3126.
44. Swanson, B. N.; Newton, D. L.; Roller, P. P.; Sporn, M. B. Biotransformation and biological activity of N-(4-hydroxyphenyl) retinamide derivatives in rodents. J. Pharmacol. Exp. Ther. 1981, 219, 632-637. (Pubitemid 12248819)
45. Peng, Y.-M.; Dalton, W. S.; Alberts, D. S.; Xu, M.-J.; Lim, H.; Meyskens, F. L., Jr. Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. Int. J. Cancer 1989, 43, 22-26. (Pubitemid 19039109)
46. Borutinskaite, V. V.; Navakauskiene, R.; Magnusson, K.-E. Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells. Ann. N.Y. Acad. Sci. 2006, 1091, 346-355. (Pubitemid 47092249)
47. Kuo, H.-S.; Hsu, F.-N.; Chiang, M.-C.; You, S.-C.; Chen, M.-C.; Lo, M.-J.; Lin, H. The role of Cdk5 in retinoic acid-induced apoptosis of cervical cancer cell line. Chin. J. Physiol. 2009, 52, 23-30.
48. Doane, A. S.; Danso, M.; Lal, P.; Donaton, M.; Zhang, L.; Hudis, C.; Gerald, W. L. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25, 3994-4008. (Pubitemid 43990755)
49. Lal, P.; Tan, L. K.; Chen, B. Correlation of Her-2 status with estrogen and progesterone receptors and histologic features in 3655 invasive breast carcinomas. Am. J. Clin. Pathol. 2005, 123, 541-546. (Pubitemid 40418549)
50. Lacroix, M.; Toillon, R.-A.; Leclercq, G. p53 and breast cancer, an update. Endocr.-Relat. Cancer 2006, 13, 293-325. (Pubitemid 43886660)
51. Rishi, A. K.; Gerald, T. M.; Shao, Z.-M.; Li, X.-S.; Baumann, R.-G.; Dawson, M. I.; Fontana, J. A. Regulation of the human retinoic acid receptor R gene in the estrogen receptor negative human breast carcinoma cell lines SKBR-3 and MDA-MB-435. Cancer Res. 1996, 56, 5246-5252. (Pubitemid 26383043)
52. Shiau, R.-J.; Chen, K.-Y.; Wen, Y.-D.; Chuang, C.-H.; Yeh, S.-L. Genistein and β-carotene enhance the growth-inhibitory effect of trichostatin in A549 cell. Eur. J. Nutr. 2010, 49, 19-25.
53. Liu, J.-P.; Wei, H.-B.; Zheng, Z.-H.; Guo, W.-P.; Fang, J.-F. Celecoxib increases retinoid sensitivity in human colon cancer cell lines. Cell. Mol. Biol. Lett. 2010, 15, 440-450.
54. Gediya, L. K.; Khandelwal, A.; Patel, J.; Belosay, A.; Sabnis, G.; Mehta, J.; Purushottamachar, P.; Njar, V. C. Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro. J. Med. Chem. 2008, 51, 3895-3904. (Pubitemid 351956518)
55. Jones, H. E.; Eaton, C. L.; Barrow, D.; Dutkowski, C.; Griffiths, K. Response of cell growth and retinoic acid receptor expression to retinoic acid in neoplastic and non-neoplastic prostate cell lines. Prostate 1997, 30, 174-182. (Pubitemid 27149276)
56. Farhana, L.; Dawson, M. I.; Dannenberg, J. H.; Xu, L.; Fontana, J. A. SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule-mediated nuclear factor-?B activation, c-Fos/ c-Jun expression, and cellular apoptosis. Mol. Cancer Ther. 2009, 8, 1625-1635.
57. Farhana, L.; Dawson, M. I.; Xia, Z.; Aboukameel, A.; Xu, L.; Liu, G.; Das, J. K.; Hatfield, J.; Levi, E.; Mohammad, R.; Fontana, J. A. Adamantyl-substituted retinoid-related molecules induce apoptosis in human acute myelogenous leukemia cells. Mol. Cancer Ther. 2010, 9, 2903-2913.
58. Dalvit, C; Flocco, M.; Knapp, S.; Mostardini, M.; Perego, R.; Stockman, B. J.; Veronesi, M.; Varasi, M. High-throughput NMR-based screening with competition binding experiments. J. Am. Chem. Soc. 2002, 124, 7720-7709.
59. Shortridge, M. D.; Hage, D. S.; Harbison, G. S.; Powers, R. Estimating protein-ligand binding affinity using high-throughput screening by NMR. J. Comb. Chem. 2008, 10, 948-958.
60. Scheiner, S.; Kar, T.; Pattanayak, J. Comparison of various types of hydrogen bonds involving aromatic amino acids. J. Am. Chem. Soc. 2002, 124, 13257-13264. (Pubitemid 35247136)
61. Kov-acs, A.; Varga, Z. Halogen acceptors in hydrogen bonding. Coord. Chem. Rev. 2006, 250, 710-727.
62. Chao,W.;Hobbs, P.D.; Jong, L.; Zhang, X.-K.; Zhang, Y.;Wu,Q.; Shroot, B.; Dawson, M. I. Effects of receptor class-and subtype-selective retinoids and an apoptosis-inducing retinoid on the adherent growth of the NIH:OVCAR-3 ovarian cancer cell line in culture. Cancer Lett. 1997, 115, 1-7. (Pubitemid 27139849)
63. Tzimas, G.; Thiel, R.; Chahoud, I.; Nau, H. The area under the concentration-time curve of all-trans-retinoic acid is the most suitable pharmacokinetic correlate to the embryotoxicity of this retinoid in the rat. Toxicol. Appl. Pharmacol. 1997, 143, 436-444. (Pubitemid 27183561)
64. Zile, M. H.; Inhorn, R. C.; DeLuca, H. F. Metabolism in vivo of all-trans-retinoic acid. J. Biol. Chem. 1982, 257, 3544-3550.
65. Disdier, B.; Bun, H.; Placidi, M.; Durand, A. Excretion of oral 9-cis-retinoic acid in the rat. Drug Metab. Dispos. 1996, 24, 1279-1281. (Pubitemid 26423070)
66. Howell, S. R.; Shirley, M. A.; Grese, T. A.; Neel, D. A.; Wells, K. E.; Ulm, E. H. Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors. Drug Metab. Dispos. 2001, 29, 990-998. (Pubitemid 32605914)
67. Gorman, G. S.; Coward, L.; Kerstner-Wood, C.; Cork, L.; Kapetanovic, I. M.; Brouillette, W. J.; Muccio, D. D. In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab. Dispos. 2007, 35, 1157-1164. (Pubitemid 46956437)
68. Mizojiri, K.; Okabe, H.; Sugeno, K.; Misaki, A.; Ito, M.; Kominami, G.; Esumi, Y.; Takaichi, M.; Harada, T.; Seki, H.; Inaba, A. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8- tetramethyl-2-naphthyl)carbamoyl]benzoic acid. 4th communication: Absorption, metabolism, excretion and plasma protein binding in various animals and man. Arzneimittelforschung 1997, 47, 259-269. (Pubitemid 27173539)
69. Hashimoto, S.; Mizobuchi, M.; Kuroda, T.; Okabe, H.; Mizojiri, K.; Takahashi, S.; Kikuchi, J.; Terui, Y. Biotransformation of a new synthetic retinoid, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid (Am-80), in the rat. Structure elucidation of themetabolites by mass and NMR spectrometry. Xenobiotica 1994, 24, 1177-1193.
70. Adamas, D. H.; Whittaker, V. P. The characterization of the esterases of human plasma. Biochem. J. 1949, 44, 62-70.
71. Ognyanov, V. I.; Balan, C.; Bannon, A.W.; Bo, Y.;Dominguez,C.; Fotsch, C.; Gore, V. K.; Klionsky, L.; Ma, V. V.; Qian, Y.-X.; Tamir, R.; Wang, X.; Xi,N.; Xu, S.; Zhu, D.; Gavva, N. R.; Treanor, J. J. S.;Norman, M. H. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl- 1H-benzimidazoles. J. Med. Chem. 2006, 49, 3719-3742. (Pubitemid 43902478)
72. Goodman, A. J.; Stanforth, S. P.; Tarbit, B. Desymmetrization of dichloroazaheterocycles. Tetrahedron 1999, 55, 15067-15070.
73. Murugesan, N.; Gu, Z.; Fadnis, L.; Tellew, J. E.; Baska, R. A. F.; Yang, Y.; Beyer, S. M.; Monshizadegan, H.; Dickinson, K. E.; Valentine, M. T.; Humphreys, W. G.; Lan, S.-J.; Ewing, W. R.; Carlson, K. E.; Kowala, M. C.; Zahler, R.; Macor, J. E. Dual angiotensin II and endothelin A receptor antagonists: Synthesis of 20-substituted N-3- isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J. Med. Chem. 2005, 48, 171-179. (Pubitemid 40105258)
74. van den Heuvel, M.; van den Berg, T. A.; Kellogg, R. M.; Choma, C. T.; Feringa, B. L. Synthesis of a non-heme template for attaching four peptides: An approach to artificial iron(II)-containing peroxidases. J. Org. Chem. 2004, 69, 250-262. (Pubitemid 38101705)
75. Goodacre, S. C.; Williams, K.; Price, S.; Dyke, H. J.; Montana, J. G.; Stanley, M. S.; Bao, L.; Lee, W. Aza-indolyl compounds and methods of use. World Patent WO 067481, 2008.
76. Patrick, D. A.; Bakunov, S. A.; Bakunova, S. M.; Kumar, E. V. K. S.; Lombardy, R. J.; Jones, S. K.; Bridges, A. S.; Zhirnov, O.; Hall, J. E.; Wenzler, T.; Brun, R.; Tidwell, R. R. Synthesis and in vitro antiprotozoal activities of dicationic 3,5-diphenylisoxazoles. J. Med. Chem. 2007, 50, 2468-2485. (Pubitemid 46799259)
77. Touzeau, F.; Arrault, A.; Guillaumet, G.; Scalbert, E.; Pfeiffer, B.; Rettori, M.-C.; Renard, P.; Mérour, J.-Y. Synthesis and biological evaluation of new 2-(4,5-dihydro-1H-imidazol-2-yl)-3,4-dihydro-2H- 1,4-benzoxazine derivatives. J. Med. Chem. 2003, 46, 1962-1979. (Pubitemid 36532239)
78. Seol, W.; Hanstein, B.; Brown, M.; Moore, D. D. Inhibition of estrogen receptor action by the orphan receptor SHP (short heterodimer partner). Mol. Endocrinol. 1998, 10, 1551-1557. (Pubitemid 30663437)